Neutrophil Elastase Enhances Sputum Solubilization in Cystic Fibrosis Patients Receiving DNase Therapy by Papayannopoulos, Venizelos et al.
Neutrophil Elastase Enhances Sputum Solubilization in





1Department of Cellular Microbiology, Max Planck Institute for Infection Biology, Berlin, Germany, 2Clinic for Pediatric Pneumology and Immunology, Christiane Herzog
Cystic Fibrosis Center, Charite ´ Medical School, Berlin, Germany
Abstract
Cystic fibrosis patients suffer from chronic lung infection and inflammation due to the secretion of viscous sputum. Sputum
viscosity is caused by extracellular DNA, some of which originates from the release of neutrophil extracellular traps (NETs).
During NET formation neutrophil elastase (NE) partially processes histones to decondense chromatin. NE is abundant in CF
sputum and is thought to contribute to tissue damage. Exogenous nucleases are a palliative treatment in CF as they
promote sputum solubilization. We show that in a process reminiscent of NET formation, NE enhances sputum solubilization
by cleaving histones to enhance the access of exogenous nucleases to DNA. In addition, we find that in Cf sputum NE is
predominantly bound to DNA, which is known to downregulate its proteolytic activity and may restrict host tissue damage.
The beneficial role of NE in CF sputum solubilization may have important implications for the development of CF therapies
targeting NE.
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Introduction
Cystic fibrosis (CF) is a debilitating hereditary disease that often
results in early death of the affected individuals. CF is caused by
mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) [1]. The lungs of CF patients produce thick
sputum that is difficult to clear and leads to tissue damage by
promoting microbial colonization and chronic inflammation. A
palliative treatment to reduce sputum viscosity is the administra-
tion of recombinant DNase [2,3,4], indicating that extracellular
DNA contributes significantly to sputum viscosity.
CF sputum contains DNA, neutrophil elastase (NE), myeloper-
oxidase (MPO) and other neutrophil proteins [5]. Although
neutrophil granular proteins are thought to be released through
degranulation, the origin of the extracellular DNA is not well
established. The extracellular DNA was suspected to originate
from necrotic neutrophils and lung tissues rather than infecting
bacteria [6]. Recently, CF sputum was found to contain neutrophil
extracellular traps (NETs) [7]. NETs are composed of decon-
densed chromatin in complex with neutrophil antimicrobial
proteins (NETs) [8,9] that are released by dying neutrophils [10]
in order to trap and kill microbes [8,11]. NETs have been
implicated in sepsis and in murine pneumococcal pneumonia
models [12,13,14]. NET release may account for a significant
portion of the extracellular DNA and azurophilic granule proteins
found in CF sputum.
Neutrophil elastase (NE) is a neutrophil specific protease that is
required for NET formation and is implicated in CF pathogen-
esis. During NET formation, NE processes core histones to
promote chromatin decondensation and release [15]. NE is also
thought to directly damage tissues in the airways of CF patients
[16]. In clinical trials, serum leukocyte protease inhibitor (SLPI)
and a1-antitrypsin (A1AT), both NE inhibitors, reduce pulmo-
nary NE activity but are only moderately beneficial to patients
[17,18,19].
Here, we show that NE degrades the DNA-bound histones in
the sputum and enhances the ability of exogenous DNases to
reduce sputum viscosity. In addition, we find that all of the NE and
myeloperoxidase found in CF sputum are bound to DNA, a key
molecular signature of NETs. DNA is known to downregulate the
proteolytic activity of NE. Therefore, while NE activity may be
damaging to lung tissues, it is also beneficial to patients receiving
DNase therapy.
Results
NETs are present in cystic fibrosis sputum
We first examined CF sputum derived from 3 CF patients who
were not undergoing DNase therapy, for the presence of NETs or
neutrophils undergoing NET formation by immunofluorescence
microscopy. In addition to intact neutrophils (Fig. 1, i)C F
sputum contained neutrophils undergoing NET formation (Fig. 1,
ii and iii, arrows). These cells displayed decondensed nuclei
that stained with NE and MPO markers. This morphology and the
translocation of these azurophilic markers to the nucleus is
consistent with the process of NET formation [15,20]. In addition
the sputum contained decondensed extracellular DNA masses that
stained positively with NE and MPO antibodies. These amor-
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large aggregates (Fig. 1, iii, asterisk).
In order to quantitate the distribution of intact neutrophils and
neutrophils that released NETs we counted the number of intact
cells in the sputum of 2 untreated patients and 2 patients receiving
DNase therapy by microscopy (Fig. S1). The total number of
neutrophils in the sputum was estimated by comparing the MPO
activity in the whole sputum following solubilization with EGTA
to the MPO activity of an extract made from a known number of
neutrophils. To estimate the number of neutrophils that
underwent NET formation we subtracted the number of intact
neutrophils from the total number of neutrophils based on MPO
activity measurements in whole sputum solubilized in the presence
of EGTA (Fig. 1b and c). The raw data used for these
measurements are presented in Fig. S2a and b. Overall, our data
indicate a prevalence of NETs over intact neutrophils in CF
sputum. Interestingly, the sputum of patients receiving DNase
therapy contained significantly lower levels of NET-associated
MPO in comparison to the sputum of patients undergoing DNase
treatment. In contrast the number of intact cells did not vary
dramatically.
A defining characteristic of NETs is the association of
chromatin with neutrophil granular proteins such as NE and
MPO [8]. We used this property to investigate the presence of
Figure 1. The sputum of cystic fibrosis patients contains neutrophils undergoing NET formation. (a) Representative fluorescence
microscopy images of neutrophils undergoing NET formation in the sputum of CF patients. Samples were labeled with antibodies against NE (red)
and MPO (green), and with the DNA dye Hoechst (blue). CF sputum contains: (i) intact naı ¨ve neutrophils. (ii, iii) neutrophils with decondensed
chromatin where NE, MPO and DNA colocalize (arrows), (iii) large aggregates that contain DNA, MPO and NE (asterisk). Scale bar: 10 mm. (b, c) The
distribution of intact neutrophils and neutrophils that have made NETs in 2 untreated patients (P1 and P2) and 2 patients receiving DNase therapy (P3
and P4). The estimates are based on a combination of microscopic and biochemical measurements. (b) Intact cells/mL (grey) measured by
microscopy, and total cells – intact cells/mL (black). The total number of cells was estimated from MPO activity/mL of sputum measured against a
lysate derived from a known number of neutrophils. A value of 104 mg MPO/10
6 neutrophils was used to estimate the total number of neutrophils (c)
The data from (b) plotted as normalized distribution of cells.
doi:10.1371/journal.pone.0028526.g001
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DNase therapy. To minimize variation due to therapeutic regimes
of different patients we further solubilised the sputum with
micrococcal nuclease (MNase) in vitro. To detect NET complexes,
we resolved solubilized sputum by native agarose gel electropho-
resis. In this assay, the highly cationic NE and MPO purified
proteins migrate towards the anode (Fig. 2a). Interestingly, when
the soluble fraction of CF sputum digested for 6 hrs is resolved,
NE and MPO co-migrated predominantly with DNA towards the
cathode, indicating that these proteins are tightly bound to the
highly negatively-charged DNA. Furthermore, an in situ enzy-
matic assay revealed that the bound MPO is active and therefore
folded (Fig. 2a).
Histones are also cationic and their migration towards the
cathode indicates that they are also tightly bound to the negatively
charged DNA in CF sputum. The complexes that contained NE
and MPO co-migrated with low amounts of histone H3 and did
not contain histone H4 (Fig. 2a). This is consistent with previous
findings indicating that NE selectively degrades histone H4 in the
context of chromatin [15]. It is also likely that CF sputum contains
chromatin that originates from necrotic cells and not from NET
formation. Consistently, a fraction of histone H3 migrated with
DNA that was not bound to MPO or NE (Fig. 2a). Alternatively,
some of these DNA fragments may also derive from NET material
as MPO is thought to be unevenly distributed in the chromatin of
NETs [8]. Taken together, these findings suggest that a significant
portion of chromatin in CF sputum may originate from NET
formation.
To estimate the amount of NET material in the sputum, we
compared the MPO activity in solubilized sputum supernatants
Figure 2. CF sputum contains DNA in complex with MPO, NE and histones. (a) MPO and NE in CF sputum are predominantly bound to
chromatin. Purified MPO, purified NE and solubilized sputum supernatant from a representative patient (3–8) digested with nucleases for 6 hrs in the
absence of protease inhibitors, resolved by native agarose electrophoresis and blotted to nitrocellulose. MPO was detected by activity prior to gel
transfer and by immunoblotting. NE, H3 and H4 were detected by immunoblotting. DNA was detected by ethidium bromide staining. Cartoon
representation of the complexes (right) where DNA is depicted in blue and the different proteins are indicated. The cartoons are positioned next to
the area of the gel where the corresponding proteins migrate. Similar results were obtained with samples from all CF patients. (b) NET content of CF
sputum using the activity of MPO in comparison to the MPO activity of human NETs. The MPO levels in the soluble fraction of CF sputum solubilized
with nucleases from 2 patients treated with Dornase were compared to MPO levels in MNase treated NETs from a known number of human
neutrophils. Accordingly, 10
6 NETs treated with MNase gave rise to 0.92 mg soluble MPO. This ratio was used to obtain the NET equivalent/mL in CF
sputum samples. (c) Comparison of the MPO levels in CF sputum by detection of MPO in supernatants solubilized with nucleases for 2 hrs, to the
MPO content of 4.1610
4 NETs, analyzed by native gel electrophoresis and western immunoblotting. (d) Quantitation of MPO levels in (c) using band
digitization. (e) NET content in CF sputum based on native gel electrophoresis analysis of sputum supernatants solubilized with nucleases, by
comparison of the band intensities in (c). All concentrations refer to the original sputum volume.
doi:10.1371/journal.pone.0028526.g002
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derived from a known number of NETs digested with MNase
(Fig. 2b and c). Interestingly, MNase treated NETs contained
only a small fraction of the active MPO found in whole neutrophil
extracts (compare Fig. 1b and Fig. 2b). Furthermore, we
quantitated the NET content in the sputum of these patients
from the MPO levels detected by native gel electrophoresis and
western immunoblotting (Fig. 2c, d and e). Our data suggest that




NE enhances sputum solubilization
During NET formation, NE promotes the release of chromatin
by processing nuclear histones. We reasoned that NE may affect
CF sputum solubility through its ability to modify chromatin
density. To investigate the role of NE in sputum solubilization we
incubated sputum aliquots with the small molecule NE inhibitor
GW311616A (NEi) or SLPI, a serpin protein that inhibits NE.
Over the course of the incubation, we centrifuged the samples and
measured the volume of soluble supernatant. NEi, but not SLPI,
delayed sputum solubilization and supernatants could not be
collected before 6 hrs of incubation (Fig. 3a).
Since exogenous nucleases promote sputum solubilization by
fragmenting the DNA, we examined the role of NE activity in
DNA solubilization. We found that DNA digestion by the
exogenous nucleases was blocked in samples treated with NEi
but not SLPI (Fig. 3b). The inability of SLPI to inhibit
solubilization is consistent with its inability to effectively inhibit
NE activity in CF sputum (Fig. 3c). In contrast, NEi inhibited NE
activity more efficiently.
Digestion of proteins in the supernatants with Proteinase K
revealed that the solubilized DNA was approximately 200 bp long,
corresponding to the size of DNA that wraps around a single
nucleosome (Fig. 4a).
To investigate whether NE promotes sputum and DNA
solubilization by proteolytically processing the histones that
package the chromatin we examined the levels of soluble histones
over time. In the absence of NEi histones were degraded over time
(Fig. 4b). In contrast, NEi but not SLPI blocked histone
degradation. The inability of SLPI to potently inhibit NE activity
in CF sputum is consistent with its reported inactivation via
degradation by its target proteases [17,21]. Consistently, in the
absence of NEi, we detected a higher molecular weight moiety of
NE that co-migrates with A1AT, a serpin related to SLPI,
resulting from the formation of a covalent complex between NE
and its inhibitor (Fig. 4b asterisks) [22]. This observation suggests
that SLPI and other serpins are in fact targeted by proteases in CF
sputum and may be overwhelmed by the high concentration of
NE. Taken together, these data suggest that NE activity promotes
sputum solubilization by degrading histones and increasing the
accessibility of the DNA to nucleases.
Since NE activity affects the levels of solubilized DNA in CF
sputum over time, we hypothesized that if MPO is bound to
chromatin we should detect a change in its migration pattern in a
native gel that is dependent on NE activity. At 24 hrs of
incubation in the absence of NEi, we detected a shift in the
MPO migration pattern that is consistent with the near complete
fragmentation of DNA molecules. Interestingly, even after near
complete nuclease digestion, MPO did not migrate to the cathode,
indicating that the protein was still bound to short fragments of
DNA (Fig. 5a). Using a more sensitive method we detected low
levels of DNA in nuclease-treated samples at 24 hrs (Fig. 5b)
which were undetectable by ethidium bromide staining on native
agarose gels (Fig. 5a). In contrast, NEi treatment completely
blocked the shift in MPO migration pattern (Fig. 5a). These
results confirm that our native electrophoresis assay detects the
association of these positively charged proteins with DNA and can
be used for the biochemical detection of NETs in patient samples.
Furthermore, the ability of NE activity to influence MPO mobility
in this assay suggests that these proteins are part of the same
macromolecular complex in CF sputum.
Discussion
Our findings suggest that a significant amount of extracellular
DNA in the sputum of cystic fibrosis patients originates from NET
formation. In the past, the extracellular DNA found in CF sputum
was thought to originate from dying necrotic or apoptotic
neutrophils and epithelial cells [6]. However, in such a case, the
chromatin would remain condensed and would not be found in
complex with neutrophil granular proteins. NET formation is the
only known neutrophil death process that can account for both
chromatin decondensation and its association with granular
proteins. Our data (Fig. 2a) indicate that approximately half of
the total amount of DNA in the sputum is complexed with
neutrophil granular proteins. The remaining DNA may represent
Figure 3. NE enhances nuclease dependent sputum solubilization. Time course analysis of untreated (black circles) and sputum treated with
SLPI (open circles), or NEi (grey circles). (a) The sputum was solubilized by DNase administered to patients and MNase. Samples were incubated
untreated or in the presence of NEi or SLPI. At the indicated timepoints, the samples were centrifuged at 10006g for 10 min and the soluble volume
was measured. The data are plotted as the % of soluble volume against the total volume of the sample and represent the average from individual
patient measurements. (b) DNA is degraded in soluble sputum supernatants incubated with nucleases in the absence (black circles) or in the
presence of SLPI (open circles) but not when incubated with NEi (grey circles). Soluble aliquots were obtained at the indicated timepoints and DNA
was measured with the Quanti-T dsDNA assay. (c) NE activity in solubilized sputum supernatants over time. NE but not SLPI inhibits NE activity in CF
sputum. (a, b) Data from a representative CF patient sample. The same trend was obtained in all patients but the overall levels of DNA and NE activity
vary significantly amongst samples from different patients.
doi:10.1371/journal.pone.0028526.g003
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DNA that originates from necrotic cells, independent of NET
formation.
We used different approaches to quantitate the NET content in
sputum based on the levels of MPO. Notably, the levels of MPO in
whole cells and NETs formed by isolated neutrophils in vitro vary
significantly and it is unclear which figure should be used as
reference. Although here we employed both reference figures, the
conditions in the highly dense sputum may enhance the
association of MPO during NET formation in contrast NETs
derived from isolated neutrophils plated on a dish where MPO is
free to diffuse into the supernatant. Despite this problem, our data
indicate a strong prevalence of NETs over intact cells in CF
sputum. Moreover, while an extended study is required, our
limited results suggest that DNase treatment may reduce the
overall levels of neutrophil products in sputum. This decrease may
Figure 4. NE degrades histones in CF sputum. (a) The solubilized sputum samples were treated with Proteinase K to digest all proteins and were
resolved by agarose gel electrophoresis. DNA was detected by ethidium bromide staining. The released DNA is approximately 200 bp long and is
digested over time in samples where NE is active. NEi blocks the digestion of DNA after 24 hrs of incubation (asterisks). (b) MPO, NE and histones,
solubilized from nuclease-treated CF sputum in vitro, are degraded over time. Protein degradation depends on the activity of NE. Immunoblot
against MPO, histones H3 and H4 in sputum sample supernatants from one representative patient. Sputum samples from each patient in the absence
or presence of NEi, or SLPI were resolved by SDS-PAGE electrophoresis. Aliquots were collected at the indicated time points during incubation with
nucleases at 37uC. An NE/serpin complex appears (asterisk at approx. 60 kDa) in untreated and SLPI-treated sputum, which is distinct from NE alone
(arrowhead). This band is approximately 55 kDa and co-migrates with a-1-anti-trypsin (A1AT) (asterisk). NEi blocks the formation of this higher
molecular weight covalent complex between NE and A1AT, indicating that serpins are targeted and deactivated by active NE in CF sputum.
doi:10.1371/journal.pone.0028526.g004
Figure 5. NE, MPO and DNA form a complex in CF sputum. (a) NE-mediated degradation of DNA-bound proteins enhances the degradation of
DNA by exogenous nucleases and alters the migration pattern of MPO. Purified MPO or supernatants from sputum samples solubilized with
nucleases at the indicated time points, either untreated (2) or treated with NEi (+NEi), were separated by electrophoresis on agarose gels under
native conditions. A black circle with a (2) sign denotes the anode, and a red circle with the (+) denotes the cathode during electrophoresis. A line
marks where the sample was loaded. MPO was detected by incubating the gel in a solution containing hydrogen peroxide and the MPO substrate O-
phenylenediamine, which turns orange upon oxidation by the enzyme (middle panel). DNA was detected by ethidium bromide staining (right panel).
The dependence of MPO migration on the presence of DNA and NE activity suggests that these molecules are part of the same macromolecular
complex. No soluble sample could be collected at 2 hrs in the presence of NEi. (b) Low levels of DNA can be detected in excised gel slices containing
MPO in (a) using the Quant-iT dsDNA assay. (a, b) Data from a representative CF patient sample.
doi:10.1371/journal.pone.0028526.g005
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to sputum clearance, or through degradation due to increased NE
activity. Therefore, the NET prevalence in DNase-treated sputum
may be understated.
Notably, NE activity enhances chromatin degradation in
DNase-treated sputum. Our findings suggest that NE in CF
sputum is predominantly associated with DNA (Fig. 2a). DNA
binding may dampen the deleterious effects of NE on lung tissues
since it downregulates the activity of the protease [23]. We and
others have found that nuclease treatment increases the presence
of NE proteolytic activity in the solubilized sputum [3].
Interestingly, NE appears associated with small fragments of
DNA after nuclease digestion, suggesting that administering
therapeutic nucleases to patients may not enhance the activity of
NE against host lung tissue as dramatically as it would in the
complete absence of DNA. In addition to its role in chromatin
decondensation, NE has been recently shown to degrade mucin in
the airways of CF patients, which is thought to decrease immune
defense but could also contribute to sputum solubilization in a
chromatin-independent fashion [24].
Most importantly, our findings suggest that similar to its
function in NET formation, NE promotes chromatin decondensa-
tion in CF sputum by proteolytic processing of histones. This
processing promotes the decondensation of chromatin which
exposes the DNA to digestion by exogenous nucleases (Fig. 6).
This specific role of NE may have both positive and negative
effects for patients. On one hand, NE activity is required for NET
formation. Blocking NE activity in CF patients may lower sputum
viscosity by preventing NET release and chromatin decondensa-
tion. On the other hand, NE inhibitors may reduce the ability of
therapeutic nucleases to promote sputum solubilization. In
addition, the role of NETs in host defense against lung infections
remains unclear but should not be neglected. Last but not least, we
predict that small cell-permeable NE inhibitors may prove more
beneficial in reducing sputum viscosity than the less permeable
serpins, as they will inhibit more efficiently the release of
chromatin through NET formation [3].
Materials and Methods
Ethics Statement and methods for CF patient sample
collection
Sputum was expectorated spontaneously from 13 adult cystic
fibrosis patients with proven diagnosis by sweat test and genetics,
in compliance with an ethical protocol approved by the
Gescha ¨ftsfu ¨hrung der Ethikkommission der Charite ´ Universita ¨ts-
medizin. Anonimity was maintained for all samples collected. The
patients were being treated for chronic Pseudomonas aeruginosa
infections and none were colonized with Bulkholderia cepacia or
multidrug resistant Staphylococcus aureus. Processing was initiated
approximately 1 hr after donation.
Immunostaining and microscopy
Sputum was fixed in 4% parafolmadehyde, dehydrated,
embedded into paraffin and sectioned to 5 mm thin slices.
Following deparaffinization, the samples were blocked with 5%
BSA/5% donkey serum, and stained with rabbit anti-MPO (1:200)
(DAKO), mouse anti-NE (1:200) (in-house) and Hoechst DNA
dye, and fluorescent secondary antibodies (1:500) (Jackson).
Biochemical analysis of sputum
Sputum from 10 patients who received Dornase (Roche) 3–
4 hrs prior to donation was separated into 3 mL aliquots and
supplemented with 2 mL of PBS containing 10 mM calcium,
5 U/mL MNase (Sigma). One aliquot received no protease
inhibitors, another 5 mM GW311616A (Sigma-Aldrich) (NEi), and
another 5 mM SLPI (Sigma), and agitated at 37u. At the indicated
time points the samples were centrifuged at 10006g for 10 min,
the soluble volume was recorded and 200 mL aliquots of the
supernatant were removed and cleared at 150006g.
Native electrophoresis
Solubilized sputum was resolved over 1% agarose gels in
20 mM HEPES, 100 mM NaCl buffer. Gels were soaked in 5 ng/
mL ethidium bromide solution for DNA detection and in a
solution containing 0.1 mg/mL of O-phenylenediamine and
1m M H 2O2 to detect MPO activity. Gel contents were
transferred onto PVDF membranes by semi-dry blotting.
Western immunoblotting
Primary antibodies: anti-H3 (1:10000), anti-H4 (1:5000) (Up-
state), anti-NE (1:200) (Abcam ab21595), anti-MPO (1:10000)
(DAKO), anti-a1AT (1:500) (DAKO). Secondary antibodies
conjugated to horseradish peroxidase (1:20000) (Jackson labs).
Enzymatic assays
DNA concentrations were measured with Quant-iT PicoGreen
dsDNA (Invitrogen). Protease activity measurements were per-
formed against 300 mM elastase substrate I (Calbiochem) by
monitoring absorbance at 410 nm. MPO activity in soluble
samples was measured in the presence of 100 mM H2O2 by
monitoring absorbance of 0.1 mg/mL of O-phenylenediamine at
450 nm.
Cell distribution measurement
Whole sputum was diluted with equal volume of PBS containing
5 mM EGTA, 5 mM EDTA and solubilized ON at 4uC. MPO
activity was measured in whole sputum aliquots and compared to
the activity of low speed supernatant derived from 5610
7
neutrophils/mL. The activity of MPO was used to estimate the
total number of neutrophils in the sputum. The number of intact
neutrophils was quantified from paraffin sections stained with
hematoxylin and eosin (H&E) and confirmed by immunofluores-
cence microscopy against NE, MPO and DNA. The neutrophils
that made NETs were determined by subtracting the number of
intact neutrophils from the total.
NET quantification
The NET content of sputum in Fig. 2b was estimated by
comparing the activity of MPO to the activity of MPO in NETs
derived from isolated human neutrophils. The NET sample was
prepared by plating 5610
6 cells and inducing with 50 nM phorbol
Figure 6. NE synergizes with therapeutic nucleases in promot-
ing CF sputum solubilization. By degrading histones, NE promotes
the relaxation of chromatin which exposes DNA to the action of
exogenously administered nucleases.
doi:10.1371/journal.pone.0028526.g006
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contrast images were obtained to determine the number of NETs.
The culture supernatant was removed and NETs were solubilized
by addition of 1 ml RPMI containing 15 u of MNase for 15 min
at 37uC. The reaction was terminated by addition of 5 mM
EGTA and samples were concentrated 106using centricon YM-3
centrifugal filter units (Millipore). Sputum samples from patients
receiving Dornase and supplemented with MNase were solubilized
for 2 hrs at 37uC and spun at 1000 g for 10 min. Supernatant
aliquots were tested for MPO activity in the presence of 100 mM
H2O2 by monitoring absorbance of 0.1 mg/mL of O-phenylene-
diamine at 450 nm. Kinetic curves were processed with the Soft
Max Pro software to obtain Vmax values. The concentration of
MPO by fitting Vmax values of samples to a linear plot generated
by enzymatic reactions with known concentrations of purified
MPO (Calbiochem) (Fig. S2a).
In addition, 10 mL of each CF sample and 10 mL containing
NETs derived from 4.1610
4 neutrophils was analyzed by native
agarose gel electrophoresis, transferred on PVDF and immuno-
blotted for MPO. Bands were quantified from scanned film images
using the ImageJ software.
Supporting Information
Figure S1 Sample images of CF sputum sections used in
determining the intact neutrophil/NET content present-
ed in Figure 1. (a) Hematoxylin and eosin stain (H&E) images of
paraffin sections from sputum isolated from 2 untreated patients
(P1 and P2) and 2 patients receiving DNase therapy (P3 and P4).
(b) Immunofluorescence images from the sputum sections in (a)
stained for MPO (green) NE (red) and the DNA dye Hoechst
(blue). Scale bars: 20 mm.
(TIF)
Figure S2 Data figures used in NET quantification
estimates presented in Fig. 1b, c and 2b. (a) Plot of the
activity of MPO (Vmax) against the concentration of MPO.
Equation of the linear fit used to calculate the amount of MPO in
experimental samples. (b) Data figures used in calculating the
intact cell/NET distribution in CF sputum samples (Fig. 1b and
c). Intact cell counts were obtained from sputum sections analyzed
by microscopy (Fig. S1a and b) The activity of MPO (Vmax) in
whole CF sputum samples solubilized with EGTA was used to
calculate the MPO concentration in CF sputum based on the
linear fit in (a). The amount of MPO in an extract derived from
5610
7 neutrophils/mL was used to estimate the total number of
neutrophils in sputum samples. The number of NET making
neutrophils was obtained by subtracting the intact cells from the
total number of cells. (c) Data figures used to estimate the NET
content in CF sputum from the activity of MPO in the soluble
fraction of sputum solubilized with nucleases, compared to the
MPO content of NETs derived from 4.1610
7 neutrophils and
solubilized with MNase, rather than the MPO content in whole
cell neutrophil extracts (Fig. 2b). Vmax values of MPO activity
measurements were used to calculate the MPO concentration in
sputum and solubilized NET samples. The amount of MPO/NET
was calculated by dividing the concentration of MPO in the
‘‘NET’’ control sample by the number of NETs measured by
microscopy prior to solubilization with Mnase.
(TIF)
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